Google
NEO Stock Analysis — NEOGENOMICS INC (Healthcare >> Diagnostics & Research)
NEO FAQ
What is NEO's P/E ratio?
NEOGENOMICS INC (NEO) currently trades at a P/E ratio of 923.93.
What is NEO's ROE?
NEOGENOMICS INC reports a Return on Equity (ROE) of -6.60%.
What is NEO's dividend yield?
NEOGENOMICS INC offers a dividend yield of 0.00%.
What is NEO's Quality Score?
Our AI rates NEO's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy NEO?
Our AI Timing Score for NEO is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does NEO belong to?
NEOGENOMICS INC is classified under the Healthcare >> Diagnostics & Research sector on the NASDAQ exchange
NEO AI Analysis Summary
Our AI summary for NEO: NEOGENOMICS INC (NASDAQ), Healthcare >> Diagnostics & Research sector. The stock currently trades at a P/E of 923.93, ROE of -6.60%, a dividend yield of 0.00%. Its financial Quality Score stands at 23/100 — fundamentals below the market average. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 15.29
Price
-0.59
(-3.72%)
Day Change
|
|
|---|
NEO, the overall quality is not good ( Quality = 23) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/E ratio is relatively high
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
44% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 94 |
| Magic Formula Rank by ROA |
457
|
| Magic Formula Rank by ROE |
457
|
| Magic Formula Rank by ROIC |
469
|
| Price | 15.29 |
| PBV / Sector |
2.63 / -29.69
|
| Earning Per Share | -0.38 |
| PE / Sector |
923.93 / 48.18
|
| PEG or PE/Growth / Sector |
-181.16 / 1.64
|
| Average 1M Daily Value |
45.21 M
GREAT
|
| Average 1W Daily Value |
61.84 M
|
| Timing Factors |
|
71% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
56% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-01 08:00:13 |
| Symbol | NEO |
| Name | NEOGENOMICS INC |
| Sector | Healthcare >> Diagnostics & Research |
| Market | NASDAQ |
| Listed Shares | 130.21 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 2,067.76 / 38,081.42 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 9490 NeoGenomics Way, Fort Myers, FL, United States, 33912
Phone: 239 768 0600
Website: https://www.neogenomics.com
Employees: 2,500
Description: NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Diagnostics & Research
Click a bubble to view stock details · Bubble size represents market capitalization share
